News – Page 853 – Endpoints News

SIGN UP

Yes, the FDA did just slap down PTC’s Duchenne MD drug for the third time

7 years ago

PDUFA date past, PTC still hasn’t said what the FDA’s verdict was; BioInvent searching for a new CEO

7 years ago

Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars

7 years ago

The Medicines Company brings out the ax, looking to jettison hundreds of jobs in top-to-bottom restructuring

7 years ago

Ablynx IPO raises $200M for its nanobody platform effort

7 years ago

Putting your subscription dollars to use: San Diego-based Brittany Meiling is joining Endpoints News

7 years ago

Publisher's note

As National Party Congress concludes, China’s FDA seeks to write widely-anticipated drug reforms into law

7 years ago

Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics

7 years ago

What’s driving the rapid growth of the top 20 biopharma companies in the world?

7 years ago

Imprimis spins out a new biotech focused on eye drugs; Alzheimer’s groups back PhII study at Amylyx

7 years ago

Eyeing a big heart failure market, scPharmaceuticals aims for $100M IPO

7 years ago

In an update, Gilead spotlights top-line hits amid a mixed set of PhII data for its $600M NASH drug

7 years ago

Tiny hep B drug combo study touts potential of a ‘functional cure’ at little-known Replicor

7 years ago

Genmab vets at low-profile Y-mAbs steer two MSK cancer drugs to the FDA after landing $50M from HBM

7 years ago

Alexion bags a blockbuster new approval for its cash cow Soliris. Now what?

7 years ago

Going all in: Biogen commits an extra $500M to Alzheimer’s blockbuster hopeful aducanumab

7 years ago

AbbVie antes up $225M in cash to buy into the Alzheimer's platform at Alector

7 years ago

UK’s NICE will cover $700K cost of GSK’s gene therapy; Evoke shares spike on NDA plans

7 years ago

With a pipeline from Gerngross’ Adimab, Arsanis hunts a $58M IPO for antibody development work

7 years ago

FDA adds fresh ‘breakthrough’ for Novartis' cancer combo Tafinlar and Mekinist

7 years ago

In a setback, Global Blood Therapeutics scraps IPF program as lead drug flounders in proof-of-concept trials

7 years ago

Takeda partner Finch joins forces with Crestovo, leaping into a mid-stage microbiome study

7 years ago

GSK grabs FDA OK for new shingles vaccine, which will now tackle a key Merck franchise

7 years ago

Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca

7 years ago

First page Previous page 850 851 852853854 855 856 Next page Last page